Beyond Air, Inc. Common Stock
XAIRBeyond Air, Inc. (XAIR) is a healthcare company focused on developing and commercializing portable, affordable oxygen therapy devices. It aims to improve respiratory care for patients with chronic lung diseases through its innovative technologies, including its Aerisa platform, which utilizes compressed oxygen and nitric oxide therapy. The company's solutions are designed to enhance patient quality of life while reducing healthcare costs.
Company News
Beyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, with a 90% customer renewal rate. The company is focusing resources on its LungFit PH nitric oxide delivery system and expects FDA approval of its second-generation device in late 2026. Management projects 2027 revenue of $16-18 million (110%+ growth) assuming Gen 2 ...
Beyond Air (XAIR) is urging stockholders to vote in favor of a reverse stock split (1-for-2 to 1-for-20 ratio) at a June 18, 2026 special meeting to maintain its Nasdaq listing. The company received a delisting notice from Nasdaq on April 7, 2026, due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business d...
Beyond Cancer, Ltd. presented updated Phase 1 trial data showing six of ten heavily pre-treated cancer patients remain alive 22-40 months after a single UNO (ultra-high concentration nitric oxide) injection. Two triple negative breast cancer patients showed no evidence of disease. The company also received a U.S. patent allowance for its propriet...
Beyond Air, Inc. (NASDAQ: XAIR) announced that Chairman & CEO Steve Lisi will participate in the 38th Annual Roth Conference on March 23, 2026, in Laguna Niguel, CA. The company will present via fireside chat and offer one-on-one meetings with investors. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on nitr...
Beyond Air commented on the publication of an independent peer-reviewed article in Intensive Care Medicine Experimental that highlights the therapeutic potential of high-dose inhaled nitric oxide (iNO) for treating respiratory infections. The article synthesized data from 27 studies showing high-dose iNO's multimodal antimicrobial activity and po...
